Yahoo Finance

PathMaker Neurosystems Receives FDA Breakthrough Device Designation For Use of the MyoRegulator® Neuromodulation Device in ALS For Slowing the Progression of Functional Symptoms

Boston, MA and Providence, RI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. ("PathMaker"), a clinical-stage neurotechnology company developing a breakthrough non-invasive approach for ...
Yahoo Finance

PathMaker Neurosystems Announces Completion of ALS Early-Feasibility Study of the MyoRegulator® Device for Non-Invasive Treatment of ALS

BOSTON, MA and PROVIDENCE, RI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. ("PathMaker"), a clinical-stage neurotechnology company developing a breakthrough non-invasive approach for ...
manilatimes

PathMaker Neurosystems Announces IRB Approval for DoD-funded Clinical Trial of the MyoRegulator Device in ALS

BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. ("PathMaker”), a clinical-stage neuromodulation company developing a breakthrough non-invasive approach to the treatment of ALS, ...
Mena FN

Pathmaker Neurosystems Receives $100,000 START Award From Massventures

BOSTON, June 08, 2022 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of ...
Business Wire

PathMaker Neurosystems Wins 2018 French-American Business Award for Startup of the Year

BOSTON & PARIS--(BUSINESS WIRE)--PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage bioelectronic medicine company developing non-invasive systems for the treatment of patients with chronic ...
FOX8 Cleveland

PathMaker Neurosystems Announces Initiation of First-in-Human Trial in ALS for Non-Invasive Neuromodulation Device

BOSTON and PARIS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the ...
Business Wire

PathMaker Neurosystems and Feinstein Institute Announce Initiation of First Clinical Trial of MyoRegulator to Treat Muscle Contraction

BOSTON & MANHASSET, N.Y.--(BUSINESS WIRE)--PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neurotechnology company developing non-invasive neurotherapy systems for the treatment of ...
Mena FN

PathMaker Neurosystems Initiates U.S. Multi-Center Trial Evaluating MyoRegulator® for the Non-Invasive Treatment of Post-Stroke Spasticity

BOSTON and PARIS, March 07, 2022 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc., (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the ...
WRBL

PathMaker Neurosystems Receives $200,000 START Award from MassVentures

BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of ...